These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 37203069)
1. Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes - A multicentric study. Chakraborty D; Mondal S; Sengupta S; Abbas Z; Chandra K; Boral S; Maiti A; Roy S; Mukherjee A; Das A; Chakraborty S; Nag P Indian J Ophthalmol; 2023 May; 71(5):1979-1985. PubMed ID: 37203069 [TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics and Outcomes of Eyes with Intraocular Inflammation after Brolucizumab: Post Hoc Analysis of HAWK and HARRIER. Singer M; Albini TA; Seres A; Baumal CR; Parikh S; Gale R; Kaiser PK; Lobach I; Feltgen N; Joshi MR; Ziemssen F; Bodaghi B Ophthalmol Retina; 2022 Feb; 6(2):97-108. PubMed ID: 33971353 [TBL] [Abstract][Full Text] [Related]
3. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259 [TBL] [Abstract][Full Text] [Related]
4. Detection and Management of Intraocular Inflammation after Brolucizumab Treatment for Neovascular Age-Related Macular Degeneration. Bodaghi B; Souied EH; Tadayoni R; Weber M; Ponthieux A; Kodjikian L Ophthalmol Retina; 2023 Oct; 7(10):879-891. PubMed ID: 37343623 [TBL] [Abstract][Full Text] [Related]
5. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map. Khanani AM; Zarbin MA; Barakat MR; Albini TA; Kaiser PK; B G; Agashivala N; Yu JS; Wykoff CC; MacCumber MW JAMA Ophthalmol; 2022 Jan; 140(1):20-28. PubMed ID: 34817566 [TBL] [Abstract][Full Text] [Related]
6. INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study. Inoda S; Takahashi H; Maruyama-Inoue M; Ikeda S; Sekiryu T; Itagaki K; Matsumoto H; Mukai R; Nagai Y; Ohnaka M; Kusuhara S; Miki A; Okada AA; Nakayama M; Nishiguchi KM; Takeuchi J; Mori R; Tanaka K; Honda S; Kohno T; Koizumi H; Miyara Y; Inoue Y; Takana H; Iida T; Maruko I; Hayashi A; Ueda-Consolvo T; Yanagi Y Retina; 2024 Apr; 44(4):714-722. PubMed ID: 38016089 [TBL] [Abstract][Full Text] [Related]
8. Short-Term Safety and Efficacy of Intravitreal Brolucizumab Injections for Neovascular Age-Related Macular Degeneration: A Multicenter Retrospective Real-World Study. Kim DJ; Jin KW; Han JM; Lee SH; Park YS; Lee JY; Lee EK; Lee JS; Kim ST; Shin MH; Lee CS; Jung HH; Jang JY; Kim M; Kim YH; Kim JH; Park KH; Park SJ; Joo K; Ji YS; Sagong M; Woo SJ Ophthalmologica; 2023; 246(3-4):192-202. PubMed ID: 36720210 [TBL] [Abstract][Full Text] [Related]
9. Visual outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration. Hirono K; Maruyama-Inoue M; Yanagi Y; Kadonosono K PLoS One; 2024; 19(4):e0302295. PubMed ID: 38635732 [TBL] [Abstract][Full Text] [Related]
10. Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab. Hoshi K; Kunikata H; Aizawa N; Yasuda M; Okabe T; Takizawa H; Abe T; Nakazawa T Int Ophthalmol; 2023 Dec; 43(12):4701-4709. PubMed ID: 38044420 [TBL] [Abstract][Full Text] [Related]